How to Read Your Compounded GLP-1 Dose (Spot Errors)

If your GLP-1 came from a compounding pharmacy, it probably arrived as a vial labeled with a concentration — something like “5 mg/mL” or “15 mg/mL” — plus a total milligram amount, rather than a fixed pre-measured dose like a brand pen delivers. That means you turn an instruction to draw a certain volume (in mL, or units on an insulin syringe) into an actual dose in milligrams, and a misread there is one of the few self-injection mistakes that can genuinely matter. This guide does one thing: it gives you the simple math to check the dose you were told to draw against the milligrams it actually delivers, shows you what normal starting doses and titration look like per the FDA labels so you have a safety anchor, and flags the patterns that mean you should pause and confirm. It is general educational information to help you ask better questions — it is not dosing advice and does not replace your prescriber or pharmacist, and compounded GLP-1s are not FDA-approved products.

Why a compounded vial is labeled differently from a brand pen

A brand pen — Wegovy, Ozempic, Zepbound, Mounjaro — is pre-dosed. The device is built around one specific milligram amount per click or per pen, you confirm or dial it, and you never decide a volume. A compounded vial is the opposite: it is a quantity of liquid at a stated concentration, and the dose is whatever volume you draw out of it. That shift — from a fixed dose set by the manufacturer to a volume you measure yourself — is exactly where confusion and error creep in.

• Concentration (mg/mL). This is the strength of the liquid — how many milligrams of drug are dissolved in each milliliter. A vial of compounded semaglutide might read “2.5 mg/mL” or “5 mg/mL”; tirzepatide is often more concentrated, e.g. “10 mg/mL” or “15 mg/mL.” Two vials with the same total milligrams can have very different concentrations, which changes how much volume a given dose takes.
• Total mg per vial. The whole amount of drug in the vial — useful for knowing how many doses it holds, but it is not your dose. Your dose is a fraction of it.
• The volume you draw (mL or units). Your instruction will tell you to pull up a certain volume — in milliliters, or, far more commonly, in units on a U-100 insulin syringe. This is the number that has to translate correctly into the milligrams your prescriber intends.
• No built-in dose limit. A pen physically stops at its dose. A syringe and an open vial do not — nothing about the hardware prevents you from drawing far too much. The only safeguard is reading the instruction and the math correctly.

For a fuller side-by-side of the two formats — including handling, storage, and what each one does and does not do for you — see our companion guide on the practical differences between a Wegovy pen and a compounded vial. The point for this article is narrower: because the vial puts the dose math on you, you should know how to run that math.

The conversion math, with worked examples

There are only two relationships to remember, and one fixed fact about insulin syringes:

• Milligrams = concentration × volume. That is, mg = (mg/mL) × mL. If you draw 0.5 mL from a 5 mg/mL vial, you have drawn 5 × 0.5 = 2.5 mg.
• On a U-100 insulin syringe, 1 mL = 100 “units.” So units = mL × 100, and mL = units ÷ 100. The “units” on the barrel are a volume marking — they are not milligrams. (Insulin units and these volume units are the same marks; the syringe was designed for insulin, but here it is just a precise way to measure a small volume.)
• Milligrams per unit = concentration ÷ 100. Because each unit is 0.01 mL, every unit you draw delivers (mg/mL) ÷ 100 milligrams. This is the handiest shortcut: work out mg-per-unit once for your vial, then any dose is just multiplication.

Here are three worked examples putting those together. Run the same arithmetic on your vial and compare the result to the milligram dose your prescriber actually told you to take.

That last row is not hypothetical — it is the shape of a real, dangerous error: a brand-new patient handed an instruction to draw 0.9 mL of a 15 mg/mL tirzepatide vial, which is 13.5 mg in a single weekly injection, when the standard starting dose is 2.5 mg. The arithmetic is what catches it: 15 × 0.9 = 13.5 mg, more than five times a normal start. The math is your check — if you can convert the volume to milligrams, you can see when the number is wrong. Our GLP-1 reconstitution and dose calculator runs this conversion for you (and handles a powder vial you have to mix first), and the GLP-1 dose plotter shows where a given dose sits on the normal titration ladder.

What a normal starting dose and titration look like (the safety anchor)

The single best protection against a dosing error is knowing what a normal dose looks like, so an abnormal one stands out. The FDA-approved brand products follow slow, stepwise dose ladders, and although a compounded product is not the same FDA-approved drug, the same molecule behaves the same way in the body — so these labeled schedules are the reference point clinicians use. Here is what the prescribing information specifies.

Two facts to anchor on: a normal semaglutide start is 0.25 mg per week, and a normal tirzepatide start is 2.5 mg per week. Everything ramps up from there in roughly four-week steps, never jumping straight to the top. If you want the tirzepatide ladder in depth — the reasoning at each step and when an increase is appropriate — see when to increase your Mounjaro dose.

Why the ramp is slow on purpose

The gradual ladder is not caution for its own sake — it exists to limit the dose-dependent side effects these drugs cause. The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, which can lead to dehydration if severe, and which become more frequent and more intense at higher doses. In the pivotal semaglutide and tirzepatide trials, these GI effects clustered during dose escalation and were reported more often in the higher-dose arms^[1][2][6][7]. Starting low and stepping up slowly gives the gut time to adapt, which is why the trials — and the labels — built in the four-week minimum at each step^[1][2]. The labels also carry warnings about more serious but less common risks, including gallbladder problems and pancreatitis, which is a further reason the dose is escalated carefully rather than rushed. Jumping a brand-new patient straight to a near-maximum dose discards every bit of that built-in protection.

It is worth saying plainly: the slow ramp is also why the efficacy is real. The large weight-loss numbers people associate with these drugs — for example the STEP 1 semaglutide trial and the SURMOUNT tirzepatide trials — came from patients who were titrated up gradually over months, not from anyone who started high^[1][2][8]. A too-fast start does not get you results faster; it mostly gets you sicker.

How to spot a likely dosing error: the red flags

You do not need to be a clinician to catch most dosing errors — you need the safety anchor above and the conversion math. These are the patterns that should make you stop and confirm before you inject:

• A starting dose far above the normal start. If you are brand new to the medication and your first dose works out to much more than 0.25 mg (semaglutide) or 2.5 mg (tirzepatide), that is a red flag. A first dose of several milligrams of semaglutide, or 10–15 mg of tirzepatide, is not a normal start.
• An instruction that jumps to near-maximum in month one. The ladders above take months to reach the top. A plan that puts you at or near the maximum dose in the first few weeks skips the entire titration the trials and labels rely on.
• The milligrams you calculate don't match what the provider told you. If your prescriber said “2.5 mg to start” but the volume on your instruction converts to 13.5 mg, those two numbers disagree — and a disagreement is the error, regardless of which one is right. Do not guess which to trust.
• Units that don't match the intended mg. Confusing a dose in milligrams with a number of units on the syringe is a classic mix-up — they are different quantities. “Draw 2.5” can mean 2.5 mg or 2.5 units depending on the vial, and those are wildly different doses. If the instruction is ambiguous about which, treat that as a red flag too.
• Round, suspicious volumes. An instruction to draw something like a full 0.9 mL or nearly the whole syringe for a starting dose deserves a second look — starting doses are usually small fractions of a milliliter.

What to do if it doesn't match

If anything above triggers, here is the calm sequence — none of it requires you to inject while you sort it out:

1. Do not inject. This is the whole point. A dose you are unsure about is a dose to hold, not to give. Missing one weekly shot while you confirm is far safer than injecting a wrong amount — and our missed-dose rules by drug cover how a brief delay is handled.
2. Get written clarification from your prescriber or pharmacist. Ask them to confirm, in writing, the exact milligram dose, the vial concentration, and the exact volume or number of units to draw. A message you can re-read beats a number you half-remember from a phone call. Ask specifically: “What is my dose in milligrams, and how many units of this concentration does that equal?”
3. Double-check the math with a calculator. Run your vial's concentration and the instructed volume through the reconstitution and dose calculator to see the milligrams it actually delivers, and use the dose plotter to see whether that lands on a normal titration step. If the calculator and your provider's written answer agree, you are aligned; if they don't, you have found a real discrepancy to resolve before injecting.
4. Seek a second opinion if a too-high start is confirmed. If your prescriber confirms that they did intend a starting dose far above the normal 0.25 mg (semaglutide) or 2.5 mg (tirzepatide) ramp, it is entirely reasonable to ask why and to get a second clinical opinion before proceeding. A legitimate provider will welcome the question and explain the plan, not pressure you to inject.

One more framing, because it matters: this guide helps you verify a dose and ask the right questions — it is not dosing advice and does not replace your prescriber or pharmacist. Compounded GLP-1 medications are not FDA-approved, and concentrations, dose steps, and instructions vary between pharmacies. The math and the safety anchors here are tools for catching a clear discrepancy and knowing when to stop and confirm; the actual dosing decision is always your prescriber's to make and explain.

Related research

• GLP-1 reconstitution & dose calculator — the companion tool to this guide: enter your vial concentration (or mix a powder vial) and the volume to draw, and see the dose in milligrams and units
• GLP-1 dose plotter — see where a given dose sits on the normal titration ladder and whether it matches a standard step
• Wegovy pen vs compounded vial: practical differences — why one is pre-dosed and the other puts the dose math on you
• How to inject semaglutide — the full step-by-step subcutaneous technique, sites, rotation, and disposal
• When to increase your Mounjaro dose — the tirzepatide titration ladder in depth and when a step-up is appropriate
• GLP-1 missed-dose rules by drug — what to do when you delay or skip a weekly dose, by medication

Editorial note & disclaimer. This article is general educational information to help you read a compounded GLP-1 dose, run the conversion math, and recognize when a dose looks wrong — it is not dosing advice and is not a substitute for your prescriber or pharmacist. Compounded GLP-1 medications (compounded semaglutide and tirzepatide) are not FDA-approved, and their concentrations, dose steps, and instructions vary by pharmacy. The starting doses and titration schedules described here are FDA-label reference points for the approved brand products and are provided as a safety anchor, not as a recommendation for any individual. If a calculated dose does not match what you were told, do not inject — confirm in writing with your prescriber or pharmacist first. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-27.